Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma

doi:10.3760/cma.j.issn.1673-422X.2017.10.006

Abstract

Abstract: ObjectiveTo evaluate the efficacy of recombinant human endostatin combined with TP (paclitaxel + cisplatin) in the treatment of advanced epidermal growth factor receptor (EGFR) squamous cell lung carcinoma. MethodsFrom January 2012 to February 2015, 100 patients with squamous cell lung carcinoma in Chongqing Three Gorges Central Hospital for medical treatment were selected as the subjects. According to different treatment methods, they were divided into single group (n=50) and combined group (n=50). The single group used the TP protocol and the combined group was treated with recombinant human endostatin on the basis of the TP protocol. The therapeutic effect was evaluated according to the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1). The shortterm effects, longterm effects, adverse reactions, hospitalization time and expenses were also analyzed. ResultsThe objective effective rate in the combined group ［52.0% (26/50)］ was significantly higher than that in the single group ［16.0% (8/50)］, with a significant difference (χ2=14.429, P=0.007). The disease control rate in the combined group was higher than that in the single group (80.0% vs. 52.0%), with a significant difference (χ2=8.734, P=0.009). Compared with the patients in the single group, the median progression free survival (8.4 months vs. 6.3 months) and overall survival (17.7 months vs. 11.5 months) in the combined group were prolonged obviously, with significant differences (χ2=5.390, P=0.025; χ2=3.993, P=0.035). The incidence rates of adverse reactions in single group were basically the same compared with the combined group, and the difference was not statistically significant (all P>0.05). Compared with the single group, the hospitalization time in combined group was longer ［(23.5±2.8) weeks vs. (18.2±3.5) weeks］, and the expenses in combined group was higher ［(112 453.9±994.9) yuan vs. (87 821.4±943.2) yuan］, with significant differences (t=8.361, P＜0.001; t=127.051, P＜0.001). But the satisfaction of patients in combined group was significantly higher than that in single group (88.0% vs. 64.0%, χ2=4.210, P=0.017). ConclusionRecombinant human endostatin combined with TP regimen is effective in the treatment of advanced EGFR wildtype squamous cell lung carcinoma, and has a low incidence of adverse reactions. It is suitable for clinical application.

Key words: Neoplasms, squamous cell, Lung neoplasms, Angiostatins, Cisplatin, Paclitaxel

Wang Wei, Ren Biyong. Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma[J]. Journal of International Oncology, 2017, 44(10): 745-748.

References

［1］吕远, 姜镕, 马春华, 等. 重组人血管内皮抑制素静脉持续泵入联合窗口期动脉灌注化疗治疗晚期肺鳞癌的临床观察［J］. 中国肺癌杂志, 2015, 18 (8): 500504. DOI: 10.3779/j.issn.10093419.2015.08.05. ［2］米热古丽·阿不都热合曼, 杜探·赛肯, 刘丹玉. 吉西他滨联合顺铂一线治疗对Ⅲb～Ⅳ期肺鳞癌的疗效评价［J］. 实用肿瘤杂志, 2015, 30(5): 459462. DOI: 10.13267/j.cnki.syzlzz.2015.05.016. ［3］吴占庆, 马强, 高玉风. 重组人血管内皮抑制素联合肝动脉化疗栓塞后肝癌患者血清VEGF、HIF1α、OPN、CTGF水平变化［J］. 中国生化药物杂志, 2015, 35(6): 98101. ［4］沈钰新, 赵伟新, 王升平, 等. 重组人血管内皮抑制素单药对非小细胞肺癌肿瘤血管微环境影响的初步研究［J］. 中国癌症杂志. 2015, 25(10): 817822. DOI: 10.3969/j.issn.10073969.2015.10.011. ［5］ Bao D, Jin X, Ma Y, et al. Comparison of the structure and biological activities of wildtype and mutant livertargeting peptide modified recombinant human endostatin (rESCSP) in human hepatocellular carcinoma HepG2 cells［J］. Protein Pept Lett, 2015, 22(5): 470479. ［6］ Bao Y, Peng F, Zhou QC, et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage Ⅲ nonsmallcell lung cancer［J］. Radiother Oncol, 2015, 114(2): 161166. DOI: 10.1016/j.radonc.2014.11.039. ［7］邢镨元, 郝学志, 胡兴胜, 等. 重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用［J］. 中国肺癌杂志, 2016, 19(10): 670674. DOI: 10.3779/j.issn.10093419.2016.10.06. ［8］ Teng C, Li LI, Shen W, et al. Pleural synovial sarcoma patient treated with combined chemotherapy and Endostar, plus sunitinib maintenance therapy: a case report and review of the literature［J］. Oncol Lett, 2015, 10(2): 11411144. DOI: 10.3892/ol.2015.3311. ［9］陈青青, 王华庆, 张会来, 等. 恩度联合CHOPT方案治疗AITL的初步疗效观察［J］. 实用肿瘤杂志, 2015, 30(1): 6064. DOI: 10.13267/j.cnki.syzlzz.2015.01.016. ［10］尹竺晟, 戈伟, 罗卫. 肿瘤标志物在非小细胞肺癌患者诊断中的价值［J］. 中国医药导报, 2016, 13(23): 102105. ［11］杨剑, 卢伟, 蒋富强, 等. 重组人血管内皮抑制素联合血管介入治疗难治性晚期肺癌的临床研究［J］. 现代仪器与医疗, 2015, 21(3): 2729. DOI: 10.11876/mimt201503010. ［12］ Hirai F, Seto T, Inamasu E, et al. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced nonsquamous nonsmall cell lung cancer［J］. Oncol Lett, 2015, 9(6): 25772582. DOI: 10.3892/ol.2015.3086. ［13］付蕾, 樊青霞, 王留兴, 等. 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察［J］. 肿瘤, 2012, 32(1): 6064. DOI: 10.3781/j.issn.10007431.2012.01.011. ［14］张媛媛. 重组人血管内皮抑制素(恩度)联合化疗(GP方案)一线治疗晚期肺鳞癌的临床研究［D］. 杭州: 浙江大学, 2014. ［15］ Lin K, Ye P, Liu J, et al. Endostar inhibits hypoxiainduced cell proliferation and migration via the hypoxiainducible factor1 alpha/vascular endothelial growth factor pathway in vitro［J］. Mol Med Rep, 2015, 11(5): 37803785. DOI: 10.3892/mmr.2014.3131. ［16］戴文鑫, 吴智勇, 陈娟, 等. 重组人血管内皮抑制素在晚期非小细胞肺癌治疗中的效果观察［J］. 检验医学与临床, 2015, 12(10): 14521453. DOI: 10.3969/j.issn.16729455.2015.10.052. ［17］ Kim JS, Kim ES, Liu D, et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with nonsmallcell lung cancer［J］. Clin Lung Cancer, 2014, 15(3): 213221. DOI: 10.1016/j.cllc.2013.12.006. ［18］时昌立, 秦德华, 丁广成, 等. miR517a3p对人肺鳞癌细胞生长和转移的影响及分子机制［J］. 中国老年学杂志, 2017, 37(9): 21322134. DOI: 10.3969/j.issn.10059202.2017.09.021.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[3]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[4]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui. Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway [J]. Journal of International Oncology, 2023, 50(7): 398-406.
[5]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[6]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[7]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[8]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[9]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[10]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[11]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[12]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[13]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[14]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[15]	Guan Gege, Sun Qiushi, Wang Yuehua, Chen Dejie, Liang Jin'e. Efficacy and safety analysis of albumin paclitaxel in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2022, 49(11): 671-676.